IgGenix is a clinical-stage antibody discovery and development company with a mission to solve allergies and other immunological diseases. We believe we can empower people to live life without the constant fear of a life-threatening allergic reaction.
Clinical Trials
ACCELERATE Peanut Study
A Phase 1, randomised, double-blind clinical study to evaluate the safety and tolerability of IGNX001, an injectable, allergen-specific therapeutic.
Learn more at the ACCELERATE Peanut Study website or at ClinicalTrials.gov.
At the intersection of biotechnology and allergy, our team begins with a deep understanding of molecular immunology thanks to our SEQ SIFTER™ antibody discovery platform. We then leverage this unique understanding to develop products intended to provide faster and more sustained clinical responses. Our first lead development candidate in food allergy, a first-in-class antibody, takes a revolutionary approach to directly address allergic disease by blocking the allergic cascade.
Latest News
Clinical Pipeline
Food Allergies
Discovery
Lead Selection
IND-Enabling
Phase 1
Peanut: IGNX001
Discovery
Lead Selection
IND-Enabling
Phase 1
Allergy Program #2
Discovery
Lead Selection
IND-Enabling
Phase 1
Allergy Program #3
Discovery
Lead Selection
IND-Enabling
Phase 1
Atopic / Autoimmune
Discovery
Lead Selection
IND-Enabling
Phase 1
Atopic Dermatitis
Discovery
Lead Selection
IND-Enabling
Phase 1
The IgGenix Platform
Our single cell RNA-sequencing-based discovery platform, SEQ SIFTER™, captures extremely rare human B cells that produce IgE antibodies directly from human blood. Through our unique technology, IgGenix isolates and re- engineers fully human, high affinity, allergen-specific IgG antibodies designed to block and prevent the allergic cascade. By targeting common immunodominant antigens and their most immunodominant epitopes across patients, we intend to treat pediatric and adult patients alike.
Research
IgGenix is currently conducting research as part of Institutional Review Board-approved observational studies across the United States. IgGenix has discovered IgE antibodies from patients with a diversity of immunological diseases.
Several programs are currently in the IgGenix pipeline targeting both food and environmental allergies. Additional platform opportunities exist in other disease areas in which IgE and/or rare cells play an important role.
Food Allergies
Environmental Allergies
Publications
Preclinical efficacy of peanut-specific IgG4 antibody therapeutic IGNX001
Journal of Allergy and Clinical Immunology, Volume 154, Issue 5, p1241-1248.E7.
Frontiers in Allergy, Volume 5
Journal of Allergy and Clinical Immunology, Volume 153, Issue 1, p182-192.E7.
Abstracts
Presented at 2024 ASCIA Annual Conference
Discovery of Monoclonal IgE Autoantibodies from Atopic Dermatitis Patients
Presented at 2024 EAACI Annual Meeting
IGNX001 Inhibits Peanut-Mediated Mast Cell Activation in a Translational
Spike-In Assay Presented at 2024 EAACI Annual Meeting
The IgGenix Team
Management
Chief Executive Officer
Chief Scientific Officer
Chief Technical Officer
Scientific Co-Founders
Stanford University; Chan Zuckerberg Initiative
Kari Nadeau, M.D., Ph.D., F.A.A.A.A.I.
Harvard School of Public Health
Board of Directors
IgGenix
Khosla Ventures
Stanford University; Chan Zuckerberg Initiative
Prosperity Capital Management
Scientific Advisory Board
Kari Nadeau, M.D., Ph.D., F.A.A.A.A.I.
Harvard School of Public Health
Hans Oettgen, M.D., Ph.D.
Harvard Medical School
Stephen Quake, D. Phil.
Stanford University; Chan Zuckerberg Initiative
Scott Smith, M.D., Ph.D.
Vanderbilt University
Dale Umetsu, M.D., Ph.D.
Stanford University; University of California, San Francisco
Jim Wells, Ph.D.
University of California, San Francisco
Investors
Careers
We are a small, innovative and passionate team working in a fast-paced environment at the forefront of allergy immunology. We have exciting opportunities for enthusiastic, self-motivated, and detail-oriented individuals to join the growing team at IgGenix. IgGenix offers competitive compensation, comprehensive benefits, equity, and the opportunity for growth.
Scroll through our list of open positions and apply today!
For more information contact us at HR@IgGenix.com.
Current Job Opportunities
IgGenix is a rapidly growing company. Please check back for available positions soon.
Contact
IgGenix, Inc
681 Gateway Blvd., Floor 4
South San Francisco, CA 94080
info@IgGenix.com